Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604454341> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2604454341 endingPage "7149" @default.
- W2604454341 startingPage "7149" @default.
- W2604454341 abstract "7149 Background: Increasing options of antitumor therapies enable the modulation of treatment on an individual basis. On the diagnostic side this means a growing need to early predict the insufficient response to therapy in order to save time and costs by changing early the treatment protocol and avoiding unnecessary toxic side effects. Methods: We investigated the courses of nucleosomes (ELISA, Roche), CYFRA 21–1, CEA, NSE (ElecSys, Roche), and ProGRP (ELISA, ALSI/IBL) in sera of 311 patients with newly diagnosed, advanced non small cell lung cancer in close meshed manner during the 1st cycle and before each new cycle of 1st line chemotherapy. Therapy response was objectified by whole body CT before the 3rd cycle according to WHO-criteria. Results: In univariate analysis, patients with remission showed significantly (p<0.05) lower values of nucleosomes and CYFRA 21–1 for the pretherapeutic baseline values of cylce 1, 2, 3 (BV1, BV2, BV3), and -already during the first therapeutic week -for the area under the curve of the days 1–8 (AUC1–8) and day 8 than patients with progression. Additionally CEA (BV3, BV1–2, BV1–3), and NSE (BV2) discriminated significantly between both groups. ProGRP had no discriminating power. Among these predictors, nucleosomes (day 8) and CYFRA 21–1 (BV2) exhibited the highest PPV for progression (77.8% resp. 76.0%) with the best sensitivity (42.4% resp. 54.3%) given a 90%-specificity to patients with remission. Both markers were independent on each other and on clinical parameters (stage, performance score). In a multivariate model they could predict progression with a certainty of 100% in 29.0% of the cases -even in a subgroup of patients with ECOG 0–2. Conclusion: The combination of nucleosomes and CYFRA 21–1 offers the appealing possibility to predict early and with high certainty the insufficient response to therapy and should be included in prospective therapeutic trials. No significant financial relationships to disclose." @default.
- W2604454341 created "2017-04-14" @default.
- W2604454341 creator A5022528932 @default.
- W2604454341 creator A5026119562 @default.
- W2604454341 creator A5028938155 @default.
- W2604454341 creator A5029892324 @default.
- W2604454341 creator A5057153061 @default.
- W2604454341 creator A5058991033 @default.
- W2604454341 creator A5077502588 @default.
- W2604454341 creator A5082052842 @default.
- W2604454341 date "2004-07-15" @default.
- W2604454341 modified "2023-09-26" @default.
- W2604454341 title "Early prediction of response to chemotherapy by circulating nucleosomes and CYFRA 21–1" @default.
- W2604454341 doi "https://doi.org/10.1200/jco.2004.22.90140.7149" @default.
- W2604454341 hasPublicationYear "2004" @default.
- W2604454341 type Work @default.
- W2604454341 sameAs 2604454341 @default.
- W2604454341 citedByCount "1" @default.
- W2604454341 crossrefType "journal-article" @default.
- W2604454341 hasAuthorship W2604454341A5022528932 @default.
- W2604454341 hasAuthorship W2604454341A5026119562 @default.
- W2604454341 hasAuthorship W2604454341A5028938155 @default.
- W2604454341 hasAuthorship W2604454341A5029892324 @default.
- W2604454341 hasAuthorship W2604454341A5057153061 @default.
- W2604454341 hasAuthorship W2604454341A5058991033 @default.
- W2604454341 hasAuthorship W2604454341A5077502588 @default.
- W2604454341 hasAuthorship W2604454341A5082052842 @default.
- W2604454341 hasConcept C126322002 @default.
- W2604454341 hasConcept C143998085 @default.
- W2604454341 hasConcept C144301174 @default.
- W2604454341 hasConcept C146357865 @default.
- W2604454341 hasConcept C151730666 @default.
- W2604454341 hasConcept C2776256026 @default.
- W2604454341 hasConcept C2776694085 @default.
- W2604454341 hasConcept C38180746 @default.
- W2604454341 hasConcept C71924100 @default.
- W2604454341 hasConcept C86803240 @default.
- W2604454341 hasConcept C90924648 @default.
- W2604454341 hasConceptScore W2604454341C126322002 @default.
- W2604454341 hasConceptScore W2604454341C143998085 @default.
- W2604454341 hasConceptScore W2604454341C144301174 @default.
- W2604454341 hasConceptScore W2604454341C146357865 @default.
- W2604454341 hasConceptScore W2604454341C151730666 @default.
- W2604454341 hasConceptScore W2604454341C2776256026 @default.
- W2604454341 hasConceptScore W2604454341C2776694085 @default.
- W2604454341 hasConceptScore W2604454341C38180746 @default.
- W2604454341 hasConceptScore W2604454341C71924100 @default.
- W2604454341 hasConceptScore W2604454341C86803240 @default.
- W2604454341 hasConceptScore W2604454341C90924648 @default.
- W2604454341 hasIssue "14_suppl" @default.
- W2604454341 hasLocation W26044543411 @default.
- W2604454341 hasOpenAccess W2604454341 @default.
- W2604454341 hasPrimaryLocation W26044543411 @default.
- W2604454341 hasRelatedWork W1987468340 @default.
- W2604454341 hasRelatedWork W2083483287 @default.
- W2604454341 hasRelatedWork W2277416945 @default.
- W2604454341 hasRelatedWork W2358450743 @default.
- W2604454341 hasRelatedWork W2361700749 @default.
- W2604454341 hasRelatedWork W2381460883 @default.
- W2604454341 hasRelatedWork W2411442805 @default.
- W2604454341 hasRelatedWork W2413020017 @default.
- W2604454341 hasRelatedWork W2480785262 @default.
- W2604454341 hasRelatedWork W3031390371 @default.
- W2604454341 hasVolume "22" @default.
- W2604454341 isParatext "false" @default.
- W2604454341 isRetracted "false" @default.
- W2604454341 magId "2604454341" @default.
- W2604454341 workType "article" @default.